BIORA THERAPEUTICS INC (BIOR) Stock Price, Quote, News and Overview
NASDAQ:BIOR - Nasdaq - US74319F3055 - Common Stock - Currency: USD
BIOR Quote, Performance and Key Statistics
0.5597
-0.79 (-58.54%)
The current stock price of BIOR is 0.5597 USD. In the past month the price decreased by -79.42%. In the past year, price decreased by -95.88%.
BIOR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About BIOR
Company Profile
Biora Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 58 full-time employees. The company went IPO on 2020-06-19. Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and systemic, needle-free delivery of biotherapeutics. The Company’s pipeline includes two therapeutic delivery platforms: NaviCap and BioJet. The NaviCap, targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract. The BioJet, systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. The company has two demonstration drug-device combination programs for the BioJet platform, BT-200 (GLP-1 receptor agonist) and BT-002 (adalimumab variant). Its other two programs include BT-600 (NaviCap + tofacitinib) and BT-001 (NaviCap + variant of adalimumab) for the treatment of ulcerative colitis.
Company Info
BIORA THERAPEUTICS INC
4330 La Jolla Village Drive, Suite 200
San Diego CALIFORNIA US
Employees: 58
Company Website: https://www.bioratherapeutics.com/
Investor Relations: https://investors.bioratherapeutics.com/
Phone: 18552932639
BIORA THERAPEUTICS INC / BIOR FAQ
What is the stock price of BIORA THERAPEUTICS INC today?
The current stock price of BIOR is 0.5597 USD. The price decreased by -58.54% in the last trading session.
What is the ticker symbol for BIORA THERAPEUTICS INC stock?
The exchange symbol of BIORA THERAPEUTICS INC is BIOR and it is listed on the Nasdaq exchange.
On which exchange is BIOR stock listed?
BIOR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIORA THERAPEUTICS INC stock?
7 analysts have analysed BIOR and the average price target is 34.68 USD. This implies a price increase of 6096.18% is expected in the next year compared to the current price of 0.5597. Check the BIORA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIORA THERAPEUTICS INC worth?
BIORA THERAPEUTICS INC (BIOR) has a market capitalization of 2.53M USD. This makes BIOR a Nano Cap stock.
How many employees does BIORA THERAPEUTICS INC have?
BIORA THERAPEUTICS INC (BIOR) currently has 58 employees.
Is BIORA THERAPEUTICS INC (BIOR) expected to grow?
The Revenue of BIORA THERAPEUTICS INC (BIOR) is expected to grow by 39100% in the next year. Check the estimates tab for more information on the BIOR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIORA THERAPEUTICS INC (BIOR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BIOR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BIOR, evaluating the profitability, health, valuation and growth aspects
- BIORA THERAPEUTICS INC (BIOR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIORA THERAPEUTICS INC (BIOR) Sales and EPS estimates to see what analysts future expectations are.
- BIORA THERAPEUTICS INC (BIOR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIORA THERAPEUTICS INC (BIOR) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIORA THERAPEUTICS INC (BIOR) Stock Chart to make your own analysis
- BIORA THERAPEUTICS INC (BIOR) Latest news and press-releases to stay up to date.
Does BIORA THERAPEUTICS INC (BIOR) stock pay dividends?
BIOR does not pay a dividend.
What is the Price/Earnings (PE) ratio of BIORA THERAPEUTICS INC (BIOR)?
BIORA THERAPEUTICS INC (BIOR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-10.84).
BIOR Technical Analysis
BIOR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BIOR. BIOR may be in some trouble as it scores bad on both profitability and health.
BIOR Financial Highlights
Over the last trailing twelve months BIOR reported a non-GAAP Earnings per Share(EPS) of -10.84. The EPS decreased by -22.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -217.44% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BIOR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to BIOR. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 88.79% and a revenue growth 39100% for BIOR